

1 **Running Title:** Optimizing SARS-CoV-2 Variant of Concern Screening

2 **Keywords:** SARS-CoV-2, variant of concern, testing, public health, COVID-19

3 Optimizing SARS-CoV-2 Variant of Concern Screening: Experience from British Columbia,
4 Canada, Early 2021

5 **Authors:** Catherine A. Hogan, MD, MSc^{1,*}, Hind Sbihi, PhD^{1,2}, Agatha Jassem, PhD^{1,3}, Natalie
6 Prystajecy, PhD^{1,3}, John R. Tyson, PhD¹, Tracy D. Lee, BSc¹, Frankie Tsang, BMLSc¹,
7 Corrinne Ng, BSc¹, Loretta Janz, BA¹, Marc G. Romney, MD^{3,4}, Linda Hoang, MD, MSc^{1,3}

8 **Affiliations:**

9 ¹ British Columbia Centre for Disease Control Public Health Laboratory, Vancouver, British
10 Columbia, Canada

11 ² School of Population and Public Health, University of British Columbia, Vancouver, British
12 Columbia, Canada

13 ³ Department of Pathology and Laboratory Medicine, University of British Columbia,
14 Vancouver, British Columbia, Canada

15 ⁴ Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, British
16 Columbia, Canada

17 * Address for correspondence:

18 Catherine A. Hogan, British Columbia Centre for Disease Control

19 655 W 12th Ave, Room 2054, Vancouver, British Columbia, Canada

20 Email: catherine.hogan@bccdc.ca; Phone (604) 707-5667

21 **Abstract**

22 Comprehensive and timely testing is required for SARS-CoV-2 variant of concern (VoC)
23 screening. Whole genome sequencing (WGS) provides the broadest means to detect circulating
24 VoCs, but requires longer turnaround time than targeted molecular testing by quantitative
25 polymerase chain reaction (qPCR). We demonstrated the feasibility of a combined testing
26 approach for VoC prevalence assessment in British Columbia, and showed high concordance
27 between qPCR testing and WGS. This directly informed wider VoC screening strategy
28 implementation, and public health efforts.

29

30 **Text (680 words)**

31 *Introduction*

32 Identification of mutations in the SARS-CoV-2 genome has led to the recognition of
33 variants of concern (VoCs) based on their association with increased transmissibility, clinical
34 severity, and/or reduced vaccine efficacy (1-5). Globally, lineages B.1.1.7, B.1.351, and P.1
35 represent the three currently circulating VoCs (6). Whole genome sequencing (WGS) provides
36 the most comprehensive means to detect circulating VoCs, but requires considerable resources
37 and time to perform. VoC screening workflows using quantitative polymerase chain reaction
38 (qPCR) optimize testing capacity and turnaround time to enable appropriate and timely public
39 health interventions (7, 8).

40 *Methods*

41 The British Columbia Centre for Disease Control Public Health Laboratory (BCCDC
42 PHL) serves as the reference laboratory for the province. A combined VoC testing strategy based
43 on direct WGS and targeted N501Y mutation qPCR was employed to estimate point prevalence
44 (**Appendix Figure 1**) based on samples resulted as positive for SARS-CoV-2 from January 30th
45 to February 5th 2021. Specimens not tested directly by WGS were screened by an assay targeting
46 the envelope (*E*) gene and N501Y mutation, which detects but does not differentiate the three
47 main VoCs, in two laboratories (**Supplementary methods**). Specimens with a detected N501Y
48 mutation underwent confirmatory testing and typing by WGS (**Supplementary methods**).
49 Ongoing surveillance was continued from February 6th to March 6th 2021 to monitor evolution in
50 VoC prevalence. Epidemiologic and laboratory data collection was performed based on linkage

51 of provincial databases. This work was conducted under the public health mandate and
52 institutional review board approval was waived.

53 *Results*

54 A total of 3,024 specimens underwent either direct WGS or screening by N501Y assay,
55 representing over 97% of the 3,101 SARS-CoV-2-positive samples in British Columbia for the
56 sampling period (**Figure 1**). The prevalence of VoCs by both pathways, direct WGS and N501Y
57 qPCR screening, was below 1%. Of the 27 individuals with a confirmed VoC, the median age
58 was 28 years (interquartile range, 20-40), and 11 were female. A total of 23 B.1.1.7 and 4
59 B.1.351 lineages were confirmed, and there was no P.1 lineage identified during this period
60 (**Table 1**). Geographical stratification revealed confirmed cases were concentrated in two health
61 authorities (**Appendix Figure 2**). Furthermore, direct WGS enabled the identification of one
62 case of B.1.525 lineage (**Appendix Figure 2**), which pointed to the recent emergence of a
63 lineage of Nigerian origin in Canada during this time period (9). Continued surveillance by
64 N501Y screening revealed a progressive increase in VoC prevalence in British Columbia,
65 reaching over 10% by the end of February 2021 (**Appendix Table 1**).

66 *Discussion*

67 Results from this point prevalence study of over 3,000 specimens demonstrated the
68 feasibility of a province-wide combined VoC screening strategy incorporating WGS and N501Y
69 qPCR screening, and showed low prevalence of VoCs with predominance of B.1.1.7 lineage in
70 British Columbia in early 2021. This assessment provided the critical prevalence data required to
71 benchmark VoC burden, and to inform planning of an optimized VoC detection strategy moving
72 forward.

73 The BCCDC PHL currently performs the highest proportion of WGS in Canada, with up to 25%
74 of SARS-CoV-2-positive specimens sequenced. However, this high-complexity approach
75 necessitates specialized equipment and expertise, and computationally-intensive analysis that
76 prolongs result turnaround time. Thus, even in specialized centralized settings, VoC testing
77 alternatives are needed. In this study, given that most cases identified by N501Y screen were
78 confirmed as VoCs, increasing the proportion of PCR-based screening over WGS upfront was
79 deemed appropriate. Based on these data, the N501Y screening strategy was expanded to clinical
80 laboratories across the province to decentralize testing, increase testing capacity, and reduce
81 turnaround time to presumptive VoC identification. Subsequent point prevalence assessments
82 based on this decentralized model are now planned for ongoing surveillance. However, a
83 limitation of this approach is that emergence of variants devoid of N501Y mutation such as the
84 recently-recognized B.1.525, reported here, may be underestimated due to failure of detection by
85 qPCR targets employed, and requires alternative qPCR assays for identification (9, 10).

86 In summary, this study demonstrated the feasibility of a combined targeted and WGS testing
87 strategy for VoC prevalence assessment in one Canadian province, which will be instrumental
88 for continued VoC surveillance, and to inform public health efforts.

89 **Acknowledgments**

90 We thank the molecular, virology, bacteriology staff and microbiologists of the BCCDC
91 Public Health Laboratory for their contribution toward testing, without which this work would
92 not have been possible. We thank Rebecca Hickman, BSc and Ji-In Hum, BSc for their
93 contributions toward test procedure development and result interpretation. We thank Chris Fjell,
94 PhD, Braeden Klaver, MPH and Yayuk Joffres, MPH, and the BCCDC data analytics team for

95 implementing the data collection and entry systems that enabled this work. We thank Drs. Nancy
96 Matic, MD and Christopher Lowe, MD and the virology laboratory staff from St. Paul's Hospital
97 for sharing and verifying VoC data. We also thank the British Columbia Association of Medical
98 Microbiologists for sharing samples and data that enabled province-wide data collection, and
99 testing.

100 **Funding**

101 None

102 **Disclosure**

103 None

104

105

106

107

108

109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151

References

1. Walensky RP, Walke HT, Fauci AS. 2021. SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities. *JAMA* doi:10.1001/jama.2021.2294.
2. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, Slayton RB, Tong S, Silk BJ, Armstrong GL, Biggerstaff M, Dugan VG. 2021. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. *MMWR Morb Mortal Wkly Rep* 70:95-99.
3. Muik A, Wallisch AK, Sanger B, Swanson KA, Muhl J, Chen W, Cai H, Maurus D, Sarkar R, Tureci O, Dormitzer PR, Sahin U. 2021. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science* 371:1152-1153.
4. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell TW, Tully DC, Washburne AD, Wenseleers T, Gimma A, Waite W, Wong KLM, van Zandvoort K, Silverman JD, Group CC-W, Consortium C-GU, Diaz-Ordaz K, Keogh R, Eggo RM, Funk S, Jit M, Atkins KE, Edmunds WJ. 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* doi:10.1126/science.abg3055.
5. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. 2021. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. *BMJ* 372:n579.
6. GISAID. 2021. Tracking of Variants. <https://www.gisaid.org/hcov19-variants/>. Accessed February 20 2021.
7. ECCDC. 2021. Sequencing of SARS-CoV-2: first update.
8. ECCDC. 2021. Methods for the detection and identification of SARS-CoV-2 variants. <https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants.pdf>. Accessed March 13 2021.
9. GISAID. 2021. B.1.525 2021-02-20. https://cov-lineages.org/global_report_B.1.525.html. Accessed March 12 2021.
10. Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, Regue H, Semanas Q, d'Aubarede C, Billaud G, Laurent F, Gonzalez C, Mekki Y, Valette M, Bouscambert M, Gaudy-Graffin C, Lina B, Morfin F, Josset L, Group CO-DHS. 2021. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to December 2020. *Euro Surveill* 26.
11. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, Bleicker T, Brunink S, Schneider J, Schmidt ML, Mulders D, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MPG, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 25:1-8.
12. Freed NE, Vlckova M, Faisal MB, Silander OK. 2020. Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. *Biol Methods Protoc* 5:bpaa014.

152 **Table 1. Epidemiologic and laboratory characteristics of the 28 individuals with**
 153 **presumptive or confirmed SARS-CoV-2 variants of concern identified in the study.**


Detection pathway	Subject	Age group/ sex	Sample type	E gene Ct result	WGS indication	WGS result	Lineage
VoC screening	VoC-1	18-50yo; F	NP	22.47	N501Y detected	Failed	NA
	VoC-2	18-50yo; M	SG	19.28	N501Y detected	Yes	B.1.1.7
	VoC-3	>50yo; M	NP	NA	N501Y detected	Yes	B.1.351
	VoC-4	>50yo; M	NA	25.78	N501Y detected	Yes	B.1.351
	VoC-5	18-50yo; F	NP	18.65	N501Y detected	Yes	B.1.1.7
	VoC-6	18-50yo; M	NP	21.38	N501Y detected	Yes	B.1.1.7
	VoC-7	>50yo; F	NP	25.52	N501Y detected	Yes	B.1.1.7
	VoC-8	18-50yo; F	SG	34.02	N501Y detected	Yes	B.1.1.7
	VoC-9	18-50yo; M	SG	30.02	N501Y detected	Yes	B.1.351
	VoC-10	<18yo; F	NA	16.94	N501Y detected	Yes	B.1.1.7
	VoC-11	>50yo; F	NA	23.09	N501Y detected	Yes	B.1.1.7
	VoC-12	18-50yo; M	SG	23.46	N501Y detected	Yes	B.1.1.7
	VoC-13	<18yo; F	NP	29.67	N501Y detected	Yes	B.1.1.7
	VoC-14	18-50yo; M	SG	26.97	N501Y detected	Yes	B.1.1.7
	VoC-15	18-50yo; M	NP	17.04	N501Y detected	Yes	B.1.1.7
	VoC-16	18-50yo; F	NP	24.88	N501Y detected	Yes	B.1.1.7
	VoC-17	<18yo; M	NA	20.17	N501Y detected	Yes	B.1.1.7
	VoC-18	18-50yo; M	SG	26.83	N501Y detected	Yes	B.1.1.7
	VoC-19	<18yo; M	NP	27.29	N501Y detected	Yes	B.1.1.7

	VoC-20	18-50yo; M	NP	22.54	N501Y detected	Yes	B.1.1.7
	VoC-21	18-50yo; M	NA	17.14	N501Y detected	Yes	B.1.1.7
	VoC-22	18-50yo; M	NP	28.19	N501Y detected	Yes	B.1.1.7
Direct WGS	VoC-23	18-50yo; F	NP	NA	Background surveillance	Yes	B.1.1.7
	VoC-24	<18yo; F	SG	28.42	Background surveillance	Yes	B.1.1.7
	VoC-25	18-50yo; M	NP	27.70	Background surveillance	Yes	B.1.351
	VoC-26	18-50yo; F	NP	15.98	Background surveillance	Yes	B.1.1.7
	VoC-27	18-50yo; F	NP	34.83	Cluster investigation	Yes	B.1.1.7
	VoC-28	>50yo; M	SG	25.96	Targeted surveillance	Yes	B.1.1.7

154 Ct: cycle threshold; F: female; M: male; NA: not available; NP: nasopharyngeal; SG: saline
 155 gargle; VoC: variant of concern; WGS: whole genome sequencing; yo: years old.

156

157



158

159 **Figure 1.** Flowchart of the screening and direct WGS testing results. The prevalence of SARS-
 160 CoV-2 variants of concern was <1% in both pathways. Most specimens were identified as
 161 B.1.1.7 lineage, and there was no P.1 lineage identified. One specimen underwent WGS twice
 162 but generated only an incomplete genome; for prevalence analysis, this specimen was considered
 163 as a confirmed VoC.

164 BC: British Columbia; BCCDC: British Columbia Centre for Disease Control; CI: confidence
 165 interval; PCR: polymerase chain reaction; SARS-CoV-2: severe acute respiratory syndrome
 166 coronavirus 2; SPH: St Paul’s Hospital; VoC: variant of concern; WGS: whole genome
 167 sequencing.

168

169 **Supplementary methods**

170 **N501Y mutation screening**

171 **BCCDC**

172 The British Columbia Centre for Disease Control (BCCDC) public health laboratory developed a
173 real-time, duplex reverse transcription polymerase chain reaction assay targeting the envelope
174 (*E*) gene and the N501Y mutation (A23063T) of the Spike (S) protein. The *E* gene probe was
175 used to confirm detection of SARS-CoV-2 RNA in the specimen, as previously described by
176 Corman *et al.*(11) The N501Y mutation is detected in the three main currently circulating
177 Variants of Concern (VoCs): lineage B.1.1.7 (variant first described in the UK), B.1.351 (variant
178 first described in South Africa), and lineage P.1 (variant described in Brazil). Briefly, total
179 nucleic acids were extracted from 200µL of upper respiratory specimen matrix (universal
180 transport medium or saline) using the Applied BioSystems MagMax™ Express 96 Nucleic Acid
181 Extractor and the MagMax Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher Scientific,
182 Waltham, MA) according to the manufacturer's recommendations. Real-time RT-PCR was
183 performed using the TaqMan Fast Virus Master Mix (Thermo Fisher Scientific) on the Applied
184 Biosystems 7500 FAST real-time PCR system (Thermo Fisher Scientific). PCR set-up was
185 performed using a volume of 5µL of patient specimen extract, for a final reaction volume of
186 20µL.

187

188 **St. Paul's Hospital**

189 The St. Paul's Hospital Clinical Microbiology Laboratory developed a real-time, reverse
190 transcription polymerase chain reaction assay targeting the *E* gene and the N501Y mutation
191 (A23063T) of the Spike (S) protein. Following extraction of viral RNA, SARS-CoV-2 detection
192 was performed using the LightMix® ModularDx SARS-CoV (COVID19) E-gene assay (TIB
193 Molbiol, Berlin, Germany), or with the combined extraction and amplification automated
194 cobas® SARS-CoV-2 Test (Roche Molecular Diagnostics, Laval, QC) using the cobas® 6800
195 instrument. A smaller number of clinical samples were tested using Xpert® Xpress SARS-CoV-
196 2/Flu/RSV (Cepheid, Sunnyvale, CA). Positives for SARS-CoV-2 were re-extracted and then
197 screened for N501Y Spike (S) protein mutation with the VirSNIp SARS-CoV-2 Mutation Assays
198 for Strain Surveillance (TIB Molbiol) using Roche LightCycler 480® (Roche Molecular
199 Diagnostics, Laval, QC). For the PCR reaction, 5 µL of extracted sample were added to the
200 reaction mixture as per the manufacturer's instructions, and results were interpreted based on an
201 analysis of amplification and melting curves.

202

203

204 **BCCDC WGS testing**

205 Whole genome sequencing was performed at the BCCDC PHL. In brief, SARS-CoV-2 RNA was
206 extracted using the Applied BioSystems MagMax™ Express 96 Nucleic Acid Extractor and the
207 MagMax Viral/Pathogen Nucleic Acid Isolation Kit (Thermo Fisher). Viral RNA was reverse
208 transcribed into cDNA using Thermo SuperScript IV, and a two pool multiplex PCR with
209 primers tiled across the entire SARS-CoV-2 genome, in 29 ~1200bp segments, was
210 performed.(12) DNA libraries for whole genome sequencing on a MiSeq instrument (Illumina,
211 San Diego) were prepared using DNA Prep Library Preparation Kit (Illumina). SARS-CoV-2

212 whole genome consensus sequences and mutation compositions were generated using a modified
213 Nextflow pipeline for running the ARTIC network's (<https://artic.network/ncov-2019>)
214 fieldbioinformatics tools (<https://github.com/BCCDC-PHL/ncov2019-artic-nf>). Reports
215 detailing SARS-CoV-2 lineage information, sequencing QC metrics and mutational profiles were
216 generated using ncov-tools from the Simpson Lab (<https://github.com/jts/ncov-tools>).

217

218 **Statistical analysis**

219 Exact 95% confidence intervals for proportions were calculated using Stata v.15.1 (Stata Corp,
220 College Station, TX).

221

222
223
224
225
226
227
228
229

References

1. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.* 2020;25(3):1-8.
2. Freed NE, Vlkova M, Faisal MB, Silander OK. Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. *Biol Methods Protoc.* 2020;5(1):bpaa014.

230 **Appendix Table 1.** Variant of concern N501Y screening post-point prevalence study period,
231 British Columbia, Canada, February-March 2021


2021 Epiweek	Start date	Total positive	Total screened	Proportion screened by N501Y assay	Presumptive VoC positive	Presumptive VoC positivity
5	2021-01-31	3128	2125	67.93%	23	1.08%
6	2021-02-07	3116	1978	63.48%	56	2.83%
7	2021-02-14	3494	2442	69.89%	108	4.42%
8	2021-02-21	3653	3064	83.88%	231	7.54%
9	2021-02-28	3931	3557	90.49%	434	12.20%

232 VoC: variant of concern.

233

234

235



236


237 **Appendix Figure 1.** Comparative analytical workflow of real-time reverse transcription
238 polymerase chain reaction testing for N501Y mutation detection (left) vs whole genome
239 sequencing (WGS) (right). The WGS process is significantly more complex, requires additional
240 expertise and longer turnaround time than conventional PCR. A VoC detection strategy that
241 leverages the uses of both approaches is needed to optimize laboratory testing capacity and
242 turnaround time. (Figure created with BioRender)

243 RNA: ribonucleic acid; rRT-PCR: real-time reverse transcription polymerase chain reaction;

244 WGS: whole genome sequencing.

245

WGS confirmed SARS-CoV-2 variants, by results date, January 30, 2021 - February 5, 2021



246

247 **Appendix Figure 2.** Number of confirmed variants of concern (VoCs) in British Columbia, from

248 January 30th to February 5th 2021 by resulting date. Geographical stratification of the data

249 revealed that the confirmed VOC cases were concentrated in two health authorities, enabling

250 focused public health efforts. Lineage B.1.1.7 strongly predominated, there was a single B.1.525
251 case, and there was no lineage P.1 identified during this time period.

252 BC: British Columbia; HA: health authority; Feb: February; SARS-CoV-2: severe acute
253 respiratory syndrome coronavirus 2; WGS: whole genome sequencing.

254